Sale!

SCN9A Gene Erythermalgia primary Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The SCN9A Gene Erythermalgia Primary Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the SCN9A gene, which are associated with Primary Erythermalgia (PE), also known as Primary Erythromelalgia. This rare condition is characterized by episodes of burning pain, redness, and swelling in the extremities, triggered by warm temperatures or mild physical activity. The test is crucial for confirming a clinical diagnosis of PE, enabling personalized treatment plans, and providing valuable information for family planning. Priced at 4400 AED, the test involves collecting a DNA sample, typically through a blood draw, and analyzing it for specific genetic mutations in the SCN9A gene. Results from this test can help in the management of symptoms and improve the quality of life for individuals with Primary Erythermalgia. DNA Labs UAE ensures a comprehensive and confidential testing process, guided by genetic counselors and medical professionals.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

SCN9A Gene Erythermalgia Primary Genetic Test

Components

Price: 4400.0 AED

Sample Condition

Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery

3 to 4 Weeks

Method

NGS Technology

Test Type

Neurological Disorders

Doctor

Neurologist

Test Department

Genetics

Pre Test Information

Clinical History of Patient who is going for SCN9A Gene Erythermalgia, primary NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SCN9A Gene Erythermalgia, primary.

Test Details

Erythermalgia is a rare disorder that is characterized by episodes of intense burning pain, redness, and warmth in the extremities, particularly the hands and feet. This condition is caused by mutations in the SCN9A gene, which provides instructions for making a protein that is involved in the transmission of pain signals in the nervous system. The primary NGS genetic test for erythermalgia involves sequencing the SCN9A gene to identify mutations that may be causing the disorder. This test can be performed using a blood sample or other tissue sample from the affected individual. The results of this genetic test can be used to confirm a diagnosis of erythermalgia and to help guide treatment decisions. In some cases, individuals with this condition may benefit from medications that block the activity of the mutated SCN9A protein, which can help to reduce pain and other symptoms. Overall, the primary NGS genetic test for erythermalgia is an important tool for diagnosing and managing this rare disorder, and can help to improve the quality of life for affected individuals.

Test Name SCN9A Gene Erythermalgia primary Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for SCN9A Gene Erythermalgia, primary NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SCN9A Gene Erythermalgia, primary
Test Details

Erythermalgia is a rare disorder that is characterized by episodes of intense burning pain, redness, and warmth in the extremities, particularly the hands and feet. This condition is caused by mutations in the SCN9A gene, which provides instructions for making a protein that is involved in the transmission of pain signals in the nervous system.

The primary NGS genetic test for erythermalgia involves sequencing the SCN9A gene to identify mutations that may be causing the disorder. This test can be performed using a blood sample or other tissue sample from the affected individual.

The results of this genetic test can be used to confirm a diagnosis of erythermalgia and to help guide treatment decisions. In some cases, individuals with this condition may benefit from medications that block the activity of the mutated SCN9A protein, which can help to reduce pain and other symptoms.

Overall, the primary NGS genetic test for erythermalgia is an important tool for diagnosing and managing this rare disorder, and can help to improve the quality of life for affected individuals.